Curasan Launches CERASORB Ortho Foam in the US

CURASAN announced the first U.S. implantation of CERASORB® Ortho Foam bone graft.

This marks CURASAN’s entrance into the U.S. orthopedic bone graft substitute market, which the company estimates at over US $800MM in annual sales.

About one year ago, CURASAN's parent company announced plans for targeted expansion of sales and marketing...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us